BAPTA-AM , 1,2-bis(2-aminophenoxy)ethane-N,N,N'N'-tetraacetic acid; COX, cyclooxygenase; FAP, familial adenomatous polyposis; FBS, Fetal bovine serum; MMPs, matrix metalloproteinases; MTT, 3-(4, 5-dimethyl-thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide; NSAIDs, Non-steroidal anti-inflammatory drugs; PGs, prostaglandins; siRNA, small interfering RNA; TJ, tight junction; ZO, zonula occludens. 
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are useful drugs for alleviating pain, fever and inflammation. The anti-inflammatory action of NSAIDs is mediated via their inhibitory effect on cyclooxygenase (COX) activity and synthesis of prostaglandins (PGs), which have a strong capacity to induce inflammation.
A range of epidemiological studies have revealed that prolonged NSAID use reduces the risk of cancer, while preclinical and clinical studies have indicated that some NSAIDs are effective in the treatment and prevention of cancer (Wang et al., 2003) . Because the anti-tumor activity of NSAIDs is potent and the safety of long-time use of NSAIDs has been proven by a vast amount of clinical data, NSAIDs have attracted considerable attention as a new type of anti-tumor drug. In the USA, the FDA has approved the use of celecoxib, an NSAID, for the treatment of familial adenomatous polyposis (FAP).
PGs, such as PGE 2 , inhibit apoptosis of cancer cells and stimulate growth and invasion of cancer cells and angiogenesis (Hoshino et al., 2003; Rolland et al., 1980; Tsujii et al., 1998) . Furthermore, overexpression of COX-2 (a subtype of COX) in various tumor cells and tissues has been reported (Eberhart et al., 1994; Ristimaki et al., 1997) . Therefore, it was believed that the anti-tumor effect of NSAIDs is mediated only through the inhibition of COX. However, several lines of evidence suggest that the anti-tumor effect of NSAIDs also involves a COX-independent mechanism (Piazza et al., 1997; Reddy et al., 1999) . In order to reveal the nature of this COX-independent mechanism, we systematically searched for genes whose expression is up-regulated by indomethacin (an NSAID) in a COX-independent manner in human gastric carcinoma (AGS) cells. This study has revealed that expression of some genes encoding tight (Mima et al., 2005) .
TJs are the most apical intercellular structures in epithelial and endothelial cells and create a physiological barrier separating the apical and basolateral spaces. TJs contain transmembrane proteins such as occludin and the claudins, whose C-terminal regions interact with cytosolic proteins, such as zonula occludens (ZO)-1 (Anderson & Van Itallie, 1995; Tsukita et al., 2001) . TJs have attracted considerable attention in relation to tumor progression because a loss of TJ structure and function is frequently observed in epithelium-derived cancers (Morin, 2005) . This loss of TJ structure and function is though to promote cancer progression through allowing constitutive accessibility of cancers to nutrients and growth factors (Swisshelm et al., 2005) and other mechanism. Furthermore, alteration of expression of the proteins that constitute TJs, especially claudins has been shown to modulate various cell functions related to tumor progression in vitro (Morin, 2005; Swisshelm et al., 2005) . For example, we recently reported that overexpression of claudin-4 or suppression of expression of claudin-4 caused a decrease or an increase, respectively, in the anchorage-independent growth and migration activity of AGS cells (Mima et al., 2005) . Studies from other groups have also shown that alterations to the expression of claudins (claudin-1, 3, 4, 5) affect the invasion and migration activities and anchorage-independent growth of cancer cells (Agarwal et al., 2005; Dhawan et al., 2005; Michl et al., 2003; Miyamori et al., 2001; Oku et al., 2006) . However, the effect of expression of other claudins, including claudin-2, on cell functions related to cancer progression have remained unknown.
Among the claudins, claudin-2 is unique because its expression increases the paracellular permeability of some molecules (in other words claudin-2 decreases the function of TJs (Amasheh et al., 2002; Furuse et al., 2001) ) and its mRNA expression is (Kinugasa et al., 2000; Mankertz et al., 2004; Sakaguchi et al., 2002) .
Based on the observations described above, it is reasonable to hypothesize that NSAIDs achieve their anti-tumor activity by altering the expression of TJ proteins. In fact, we previously reported that induction of expression of claudin-4 by NSAIDs contributes to NSAID-dependent inhibition of both migration and anchorage-independent growth of cancer cells (Mima et al., 2005) . In this study, we examined the effects of various NSAIDs on the expression of various TJ proteins in AGS cells and found that NSAIDs inhibit the expression of claudin-2 specifically and extensively. Experiments using an overexpression plasmid and small interfering RNA (siRNA) revealed that expression of claudin-2 increases the invasion and migration activity of AGS cells and suggest that NSAID-dependent inhibition of the invasion and migration activity of AGS cells is due to the NSAID-dependent down-regulation of claudin-2 expression. We suggest that NSAIDs positively or negatively affect the expression of claudins, depending on the claudin species, and that this action plays an important role in conferring the chemopreventive effect of NSAIDs through inhibition of metastasis.
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Materials and methods

Chemicals and media
Ham F12, DMEM and RPMI1640 medium were obtained from Nissui Pharmaceutical
Co. HilyMax and BAPTA-AM were obtained from Dojindo Co. Fetal bovine serum (FBS), fibronectin, G418, 3-(4, 5-dimethyl-thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) and diclofenac were obtained from Sigma Co. Indomethacin was from Wako Co. Celecoxib was obtained from LKT Laboratories Inc. The plasmid psiRNA-h7SKneo was from InvivoGen and pcDNA3.1(-) and Lipofectamine (TM2000) were from Invitrogen. The RNeasy kit was obtained from Qiagen, first-strand cDNA synthesis kit was from GE Healthcare and iQ SYBR Green Supermix was from Bio-Rad.
Matrigel was from BD Biosciences and the 24-well transwells were from Costar.
Antibody against claudin-2 was from Zymed and those against claudin-4 and actin were from Santa Cruz.
Cell culture and stimulation or suppression of claudin-2 expression
AGS and KATO-III cells (human carcinoma cell lines derived from stomach) were cultured in RPMI1640 medium containing 10% FBS and T-84 (human colonic adenocarcinoma cell line) and A549 (human lung adenocarcinoma) cells were cultured in Ham F12/DMEM medium containing 5% FBS. Cells (2 x 10 5 cells per well in a 24-well plate) were cultured for 24 h and then used in the experiments. Cell viability was determined by the MTT method as previously described (Tsutsumi et al., 2002a) .
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A full-length human CLDN2 cDNA was PCR-amplified from AGS cell cDNA and cloned into pcDNA3.1(-) to create the plasmid for overexpression of claudin-2.
We used the siRNA sequence of 5'-ACCTCGGATCCTACGGGACTTCTACTTCAAGAGAGTAGAAGTCCCGTAGGA TCCTT-3' as annealed oligonucleotides for repressing claudin-2 expression. A DNA fragment encoding this siRNA was cloned into a psiRNA-h7SKneo to create the plasmid for expression of this siRNA.
Transfection of AGS cells with plasmids was carried out using Lipofectamine (TM2000) or HilyMax according to the manufacturer's protocols. The stable transfectants expressing claudin-2 or siRNA for claudin-2 were selected by immunoblotting analysis. Positive clones were maintained in the presence of 300 µg/ml G418.
Real-time RT-PCR.
Total RNA was extracted using an RNeasy kit according to the manufacturer's protocol.
Samples (2.5 µg RNA) were reverse-transcribed using a first-strand cDNA synthesis kit according to the manufacturer's instructions. Synthesized cDNA was used in real-time
RT-PCR (Chromo 4 instrument (Bio-Rad)) experiments using iQ SYBR GREEN
Supermix and analyzed with Opticon Monitor Software according to the manufacturer's instructions. The real-time PCR cycle conditions were 2 min at 50°C, followed by 10 min at 90°C and finally 45 cycles of 95°C for 30 s and 63°C for 60 s. Specificity was confirmed by electrophoretic analysis of the reaction products and by inclusion of template-or reverse transcriptase-free controls. To normalize the amount of total RNA present in each reaction, the actin cDNA was used as an internal standard. 
Immunoblotting analysis
Membrane fractions were prepared as described previously (Mullin et al., 2005) . The protein concentration of the sample was determined by the Bradford method. Samples were applied to 12% polyacrylamide gels containing SDS, subjected to electrophoresis, and proteins were then immunoblotted with each antibody.
Anoikis induction.
Anoikis induction was assayed as described (Osanai et al., 2006) , with some modifications. Dishes were coated with 1% agarose to prevent cells from adhering to the plastic cell culture dishes. Solidified agarose was equilibrated and overlaid with DMEM supplemented with 10% FBS. After treatment with trypsin, cells were applied to these plates and rotated horizontally several times to allow the cells to form spheroidal aggregations. After incubation for 7 days, cells were collected, applied to normal cell culture dishes and the number of colonies derived from viable cells were counted after incubation for 3 days.
Invasion assay.
The invasion assay was done as described previously (Larkins et al., 2006) , with some modifications. Serum free RPMI1640 medium containing 5 mg/ml matrigel was applied to the upper chamber of a 24-well transwell and incubated at 37°C for 4 h. Cell 9 suspension was applied to the matrigel and the lower chamber of the transwell was filled with culture media containing 10% FBS and 5 µg/ml fibronectin. The plate was incubated at 37°C for 24 h. Cells were removed from the upper surface of the membrane and the lower surface of the membrane was stained for 10 min with 0.5% crystal violet in 25% methanol, rinsed with distilled water and air-dried overnight. The crystal violet was then extracted with 0.1 M sodium citrate in 50% ethanol and the absorbance was measured at 585 nm.
Cell migration assays.
In vitro wound healing assays were used to assess cell migration as described previously (Mima et al., 2005; Wittchen et al., 2003) . Confluent AGS cells on a 24-well plate were used for this assay. Two linear wounds were made with a p200 pipette tip.
The cell-free area was measured before and after a 24 h incubation (healing step) by use of Scion Image software (Scion Corporation).
Statistical analysis
All values are expressed as the mean ± standard error of the mean (S.E.M. 
Results
Effect of NSAIDs on expression of claudins
We used a real-time RT-PCR technique to examine the effect of various NSAIDs on expression of claudins and other TJ proteins in AGS cells. First, we examined the effect of various NSAIDs on cell viability and determined the concentration of each NSAID required to reduce cell viability to 70% (0.35 mM indomethacin, 30 µM celecoxib, 0.2 mM diclofenac, 5 mM aspirin, 1 mM ibuprofen and 0.18 mM nimesulid). We next examined the effects of these concentrations of NSAIDs on mRNA expression of various TJ proteins (Table 1 ). The mRNA expression of CLDN4 was clearly up-regulated by all NSAIDs tested and that of CLDN1 and occludin was slightly up-regulated, as described previously (Mima et al., 2005) . Of all the proteins tested, a characteristic feature in response to the NSAIDs was identified for claudin-2: all of the NSAIDs tested suppressed the mRNA expression of CLDN2 and the extent of the suppression was more distinct than for other claudins (Table 1 ). The mRNA expression of CLDN7 and ZO-1 or CLDN3, CLDN5 and CLDN6 showed a tendency to be increased or decreased, respectively, by NSAIDs. However, for these genes the changes in expression were not observed in response to some NSAIDs and the extent of the changes were not as distinct as was observed for CLDN4 and CLDN2 (Table 1) . COX exists as two subtypes, COX-1 and COX-2. Celecoxib and nimesulid are COX-2-specific NSAIDs and thus, the results in Table 1 suggest that NSAIDs suppress the expression of CLDN2 mRNA irrespective of their COX-2 specificity.
The effect of NSAIDs on the expression of claudin-2 was also examined at the increased the amount of claudin-4, but also decreased the amount of claudin-2 in the membrane fraction (Fig. 1A) . As for claudin-4, we have previously shown similar results using whole cell extract (Mima et al., 2005) . A decrease in the amount of claudin-2 was observed with 0.1 mM diclofenac, which did not significantly affect the cell viability (data not shown), suggesting that this decrease is not a result of cell damage. Similar results were obtained with whole cell extracts (data not shown),
showing that the NSAID-induced decrease in the amount of claudin-2 in the membrane fraction is not due to an alteration of its subcellular localization. Combining the results in Table 1 and Fig. 1A , we consider that NSAIDs decrease the amount of claudin-2 through down-regulating their transcription.
We also examined the effect of NSAIDs on the expression of claudin-2 and claudin-4 in other types of cells: KATO-III and T-84 which are cell lines derived from gastric cancer and A549 is from lung cancer. As shown in Fig. 1B, indomethacin decreased or increased the amount of claudin-2 or claudin-4, respectively, in the membrane fraction of these cell lines (Fig. 1B) . Furthermore, we showed that celecoxib altered the amount of claudin-2 and claudin-4 even in KATO-III cells. It has been reported that both COX-1 and COX-2 mRNAs are expressed in AGS cells, whereas COX-2 mRNA expression is very low in KATO-III cells (Lim et al., 2001; Tsuji et al., 1996) and we confirmed these phenotypes by real-time RT-PCR analysis (data not shown). Therefore, a COX-2-specific NSAID, celecoxib, altered the amount of claudin-2 and claudin-4 even in cells lacking COX-2 expression (Fig. 1B) . Furthermore, while indomethacin inhibited both COX-1 and COX-2 at a concentration of less than 1 µM (Kawai et al., 1998) , altered expression of the claudins required higher concentrations (Fig. 1) . These findings suggest that NSAIDs affect the expression of 12 claudin-2 and claudin-4 independently of COX-inhibition. For claudin-4, we have previously shown results similar to those in Fig. 1B using whole cell extracts (Mima et al., 2005) .
Mechanism for suppression of Claudin-2 expression by indomethacin
For further confirmation that NSAIDs suppress expression of claudin-2 independently of COX-inhibition, we examined the effect of PGE 2 , a major PG in gastric mucosa, on the suppression of claudin-2 expression by indomethacin. PGE 2 (1 or 10 μM) did not affect the level of claudin-2 in either the presence or absence of indomethacin (Fig. 1C) .
Also, PGE 2 did not affect the level of claudin-4, as described previously (Mima et al., 2005 ). We previously determined the level of PGE 2 in the culture medium of AGS cells to be about 10 nM (Tsutsumi et al., 2002b) . Therefore, inhibition of PGE 2 synthesis by indomethacin does not seem to be involved in the suppression of expression of claudin-2 by indomethacin.
We recently reported that NSAIDs, due to their membrane permeabilizing activity, increase the intracellular Ca 2+ level by stimulating Ca 2+ influx across the cytoplasmic membrane (Tanaka et al., 2005; Tomisato et al., 2004a) . Furthermore, we reported that this Ca 2+ increase is responsible for the induction of expression of claudin-4 by NSAIDs: we showed that an intracellular Ca (Fig. 1D) . These results suggest that suppression of 
Role of NSAID-induced suppression of claudin-2 expression in the anti-tumor effect in vitro
In order to understand the role of suppression of claudin-2 expression in the chemopreventive effect of NSAIDs, we examined the effect of claudin-2 expression on various cell functions related to cancer progression, such as cell growth, anoikis (apoptosis induced by lack of cell-matrix interaction), and invasion and migration activity.
We constructed stable transfectants of AGS cells that continuously overexpress claudin-2. Moderate and high levels of claudin-2 expression in clone 1 and clone 5, respectively, were confirmed by immunoblotting analysis (Fig. 2A) . We also constructed stable transfectants of AGS cells that continuously express siRNA to suppress the basal expression of claudin-2 (siClaudin-2) ( Fig. 2A) . Figure 2B shows the growth curve of each clone. Growth of claudin-2-overexpressing clones (clones 1 and 5) and a claudin-2-down-regulating clone (siClaudin-2) was indistinguishable from that of each mock transfectant control, demonstrating that expression of claudin-2 does not affect the growth of AGS cells. We also examined the effect of alteration in the expression of claudin-2 on cell growth in the presence of indomethacin. Indomethacin (0.2 mM) inhibited the cell growth and alteration in the expression of claudin-2 did not affect this inhibition (Fig. 2C) .
Therefore, suppression of claudin-2 expression by NSAIDs does not seem to be involved in inhibition of cell growth by NSAIDs.
14 We also examined the effect of claudin-2 expression on induction of anoikis. As shown in Fig. 3A and B, the number of colonies (viable cell number) after incubation under conditions where there was a lack of cell-matrix interaction, was indistinguishable between claudin-2-overexpressing or claudin-2-down-regulating clone and each mock transfectant control. In the presence of 0.1 mM indomethacin, induction of anoikis was clearly inhibited and this inhibition was not affected by alteration in the expression of claudin-2 ( Fig. 3A and B) . This suggests that the expression of claudin-2 does not affect the induction of anoikis in AGS cells.
The effect of expression of claudin-2 on invasion activity of AGS cells was examined by use of a matrigel transwell assay. As shown in Fig. 4A , the claudin-2-overexpressing clone showed significantly greater cell invasion activity than the mock transfectant control. This effect was more apparent in clone 5 than in clone 1 (Fig. 4A) , being well correlated to the extent of overexpression of claudin-2 ( Fig. 2A) .
On the other hand, the claudin-2-down-regulating clone showed less cell invasion activity than the mock transfectant control (Fig. 4B) . These results suggest that expression of claudin-2 stimulates the cell invasion activity of AGS cells.
We also examined the effect of indomethacin or celecoxib on cell invasion activity. Indomethacin or celecoxib dose-dependently inhibited the cell invasion activity and this inhibitory effect was not observed in the claudin-2-overexpressing clone (Fig.   4C ). Treatment with indomethacin or celecoxib resulted in lower cell invasion activity in claudin-2-down-regulating clone (Fig. 4D) . The concentrations of indomethacin or celecoxib used in Fig. 4C and D did not affect the growth of AGS cells (data not shown).
Treatment with these concentrations of indomethacin suppressed the mRNA expression of CLDN2 in the mock transfectant control but not in the claudin-2-overexpressing clone (Fig. 4E) . Based on these results, we consider that NSAIDs inhibit cell invasion activity through suppression of claudin-2 expression.
The results in Fig. 4 suggest that the cell migration activity of AGS cells is affected by expression of claudin-2 and we tested this hypothesis using wound healing assays: we measured the cell-free area 24 h after making a wound. Since neither alterations to claudin-2 expression nor addition of indomethacin (less than 0.2 mM) affected the growth of AGS cells (Fig. 2B and data not shown) , the less cell-free area means the higher cell migration activity. As shown in Fig. 5A , claudin-2-over-expressing cells showed significantly higher cell migration activity than the mock transfectant control. On the other hand, the claudin-2-down-regulating clone showed lower cell migration activity than the mock transfectant control (Fig. 5C ).
These results suggest that expression of claudin-2 stimulates the cell migration activity of AGS cells, which is opposite to what was observed for claudin-4, the expression of which was shown to inhibit the cell migration activity of AGS cells (Mima et al., 2005) .
As shown in Fig. 5E , indomethacin inhibited the migration activity of AGS cells and this inhibitory effect was not observed in claudin-2-overexpressing cells. All of these results support the hypothesis that the suppression of claudin-2 expression by indomethacin is involved in the inhibition of cell migration activity.
Discussion
At least 24 types of claudins are known to exist ) and among them claudin-2 is unique because it is the only claudin whose expression has been shown to make TJs leaky (Amasheh et al., 2002; Furuse et al., 2001) . Results of the current study reveal that in its response to NSAIDs, claudin-2 is also unique: all of the NSAIDs tested clearly and specifically suppressed the expression of claudin-2.
We have previously shown that induction of claudin-4 expression by NSAIDs is mediated by an increase in the intracellular Ca 2+ level: thapsigargin and ionomycin which are known to increase the intracellular Ca 2+ level, induced expression of claudin-4 and the intracellular Ca 2+ chelator (BAPTA-AM) attenuated the NSAID-dependent induction of claudin-4 expression (Mima et al., 2005) . This Ca 2+ -increase is caused by stimulation of an influx of extracellular Ca 2+ due to the membrane-permeabilizing activity of NSAIDs (Tanaka et al., 2005; Tomisato et al., 2004a; Tomisato et al., 2004b) .
However, results of this study show that down-regulation of expression of claudin-2 by NSAIDs is not mediated by the same mechanism. BAPTA-AM did not affect this down-regulation. Thus, the mechanism governing NSAID-dependent inhibition of claudin-2 expression is unclear at present.
Although a number of recent papers have shown the effects of expression of various claudins on the invasion and migration activities of cancer cells (Agarwal et al., 2005; Dhawan et al., 2005; Michl et al., 2003; Oku et al., 2006) , the effects of claudin-2 expression have remained unknown. In this study we have shown that overexpression of claudin-2 or suppression of claudin-2 expression increases or decreases, respectively, the invasion and migration activities of AGS cells. Cell invasion activity mainly depends on cell migration activity and on degradation of the extracellar matrix which is mainly mediated by matrix metalloproteinases (MMPs). Since claudin-2 expression up-regulated the expression of MMPs (MMP1, MMP2 and MMP9) and stimulated MMP activity (data not shown), we believe that the claudin-2-dependent increase in cell invasion activity is due to stimulation of both cell migration activity and MMP activity.
Results of this study show that expression of claudin-2 contributes to the stimulation of invasion activity of cancer cells and thus expression of claudin-2 may contribute to tumor metastasis in vivo. It has been reported that claudin-2 expression is frequently up-regulated in clinically isolated colorectal and gastric tumors, compared to normal tissues (Aung, 2006) . It has also been reported that the extent of claudin-2 expression correlates with the degree of progression of cancer (Kinugasa et al., 2007) . Thus, the results of the current study suggest that this up-regulation of claudin-2 in cancers contributes to cancer progression.
We have previously reported, using the same cells and assay system, that expression of claudin-4 inhibited cell migration activity and anchorage-independent growth of cancer cells (Mima et al., 2005) . Here, we have shown that expression of claudin-2 does not affect the induction of anoikis (apoptosis induced by lack of cell-matrix interaction). Thus, it seems that depending on the claudin species, claudins positively or negatively affect the progression of cancer through various mechanisms.
The mechanism whereby expression of claudin-2 stimulates the migration activity of AGS cells remains unknown. One possibility is that the negative effect of claudin-2 on the function of TJs is responsible for this phenotype. Another possibility is that claudin-2 achieves this effect via a TJ-independent mechanism, as is the case for claudin-1 which was reported to translocate into the nucleus, affect cancer-related gene expression and stimulate cell invasion activity (Dhawan et al., 2005) .
NSAIDs seem to achieve their chemopreventive effect through various (Gupta & Dubois, 2001; Kismet et al., 2004) . In this study, we suggest that NSAID-dependent inhibition of invasion and migration activities involves suppression of claudin-2 expression by NSAIDs:
NSAID-dependent suppression of migration and invasion activities was not observed in the claudin-2-overexpressing clone. As described above, we have previously suggested that NSAID-dependent inhibition of migration activity involves induction of claudin-4 expression by NSAIDs (Mima et al., 2005) . Thus, these alterations in claudin expression seem to be involved in NSAID-dependent suppression of migration and invasion activities (suppression of metastasis). Screening of NSAIDs to identify molecules that potently induce claudin-4 expression and suppress claudin-2 expression may be useful for obtaining more potent NSAIDs for cancer treatment. were prepared and analyzed by immunoblotting with an antibody against claudin-2 or claudin-4. For loading control, the gels were stained with silver. 
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